What Could Come After CAR-T? Cue Is Betting On Selective Biologics

 
• By Lucie Ellis-Taitt
  
Generate a summary of this article
Listen to this article
Beta

Emerging Company Profile: Cue Biopharma, a young biotech formed on the basis of research from the Albert Einstein College of Medicine, is developing biologics engineered to selectively modulate disease-relevant T-cells to treat cancer – technology it has called the "next wave" in cancer immunotherapy.

Emerging Company Profile Regular column feature image Version 2
Cue Biopharma execs boast cell therapy biologics for cancer

Cue Biopharma Inc., a company developing biologics targeting tumor specific T-cell receptors (TCRs), believes its technology could represent the next wave of cancer immunotherapy – besting even novel chimeric antigen receptor (CAR) T-cell therapies that are yet to reach the market. Still, while Cue is excited about its technology based on promising preclinical data, lots of uncertainties remain around the mechanisms of action for biologic cell therapies.

Cue's hypothesis is based on using biologics to stimulate endogenous TCRs via the peptide major histocompatibility complex (MHC) and TCR...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Start-Ups & SMEs

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.